CyTOF immune profiling uncovers sex- and race-specific differences and cellular biomarkers for biologic response in Hidradenitis suppurativa
Recommended Citation
Wang P, Dimitrion P, Young A, Yin C, Hamzavi IH, Adrianto I, Zhou L, Mi Q. CyTOF immune profiling uncovers sex- and race-specific differences and cellular biomarkers for biologic response in Hidradenitis suppurativa. J Invest Dermatol 2024; 144:S161.
Document Type
Conference Proceeding
Publication Date
8-1-2024
Publication Title
J Invest Dermatol
Abstract
Hidradenitis suppurativa (HS) disproportionately affects African Americans and women. Whether different demographic subgroups of patients with HS exhibit distinct immune dysregulation is unknown. Furthermore, predictive biomarkers of treatment response are urgently needed. To address these gaps, we performed cytometry by time of flight (CyTOF) analysis, utilizing 30 immune markers, to measure 37 immune cell populations in whole blood from 74 patients with HS. Our cohort comprised 81% females; 50% were Black, and 41% were white. Thirty-one patients had undergone anti-TNF therapy, with 13/23 (57%) and 8/22 (36%) experiencing treatment failure with adalimumab and infliximab, respectively. We analyzed the data with respect to sex, race, Hurley stage, and treatment response. Compared to males, females exhibited higher levels of total B cells, including naive B cells and memory B cells, as well as naive CD8 αβ T cells (p<0.05). In contrast, compared to non-Blacks, Black individuals displayed elevated levels of plasmablasts, non-classical monocytes, and dendritic cells, but decreased levels of basophils and Th1 cells (p<0.05). Patients with Hurley stage 3 demonstrated increased levels of Th17 and Treg cells compared to those with stage 2 (p<0.05). Furthermore, individuals who failed adalimumab treatment exhibited a higher Th17:Treg ratio (p=0.02). Patients receiving infliximab therapy had reduced levels of NK cells and CD8 αβ T cells but increased levels of plasmablasts and intermediate monocytes. However, those who experienced treatment failure with infliximab demonstrated higher levels of intermediate monocytes and lower levels of αβ T cells, particularly central memory CD8 cells and central memory CD4 cells. Overall, our findings highlight distinct immune responses in HS based on race, sex, and disease severity. Furthermore, we identify potential Th17:Treg axis as the biomarkers for anti-TNF therapy, which may aid in elucidating pathogenesis and guiding precision medicine approaches.
Volume
144
First Page
S161
